Appendix C
Possible Combinations of Scores

There are 625 possible combinations of scores that fall under Priority Groups I through V. These are all listed below, in the priority order that would be indicated by the proposed framework. As described in Chapter 5, high prevalence of use would shift supplements to the highest priority within each Priority Group. NAD=no appropriate data.

Priority Group

Human Data

Animal Data

Structure Data

In Vitro Data

I

3

3

3

3

 

3

3

3

2

 

3

3

3

NAD

 

3

3

3

1

 

3

3

3

0

 

3

3

2

3

 

3

3

NAD

3

 

3

3

1

3

 

3

3

0

3

 

3

3

2

2

 

3

3

2

NAD

 

3

3

2

1

 

3

3

2

0

 

3

3

NAD

2

 

3

3

NAD

NAD

 

3

3

NAD

1

 

3

3

NAD

0

 

3

3

1

2

 

3

3

1

NAD

 

3

3

1

1

 

3

3

1

0

 

3

3

0

2

 

3

3

0

NAD

 

3

3

0

1

 

3

3

0

0



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Appendix C Possible Combinations of Scores There are 625 possible combinations of scores that fall under Priority Groups I through V. These are all listed below, in the priority order that would be indicated by the proposed framework. As described in Chapter 5, high prevalence of use would shift supplements to the highest priority within each Priority Group. NAD=no appropriate data. Priority Group Human Data Animal Data Structure Data In Vitro Data I 3 3 3 3   3 3 3 2   3 3 3 NAD   3 3 3 1   3 3 3 0   3 3 2 3   3 3 NAD 3   3 3 1 3   3 3 0 3   3 3 2 2   3 3 2 NAD   3 3 2 1   3 3 2 0   3 3 NAD 2   3 3 NAD NAD   3 3 NAD 1   3 3 NAD 0   3 3 1 2   3 3 1 NAD   3 3 1 1   3 3 1 0   3 3 0 2   3 3 0 NAD   3 3 0 1   3 3 0 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data II 3 2 3 3   3 NAD 3 3   3 1 3 3   3 0 3 3   3 2 3 2   3 2 3 NAD   3 2 3 1   3 2 3 0   3 2 2 3   3 2 NAD 3   3 2 1 3   3 2 0 3   3 NAD 3 2   3 NAD 3 NAD   3 NAD 3 1   3 NAD 3 0   3 NAD 2 3   3 NAD NAD 3   3 NAD 1 3   3 NAD 0 3   3 1 3 2   3 1 3 NAD   3 1 3 1   3 1 3 0   3 1 2 3   3 1 NAD 3   3 1 1 3   3 1 0 3   3 0 3 2   3 0 3 NAD   3 0 3 1   3 0 3 0   3 0 2 3   3 0 NAD 3   3 0 1 3   3 0 0 3   3 2 2 2   3 2 2 NAD   3 2 2 1   3 2 2 0   3 2 NAD 2   3 2 NAD NAD   3 2 NAD 1   3 2 NAD 0   3 2 1 2   3 2 1 NAD   3 2 1 1   3 2 1 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data II 3 2 0 2   3 2 0 NAD   3 2 0 1   3 2 0 0   3 NAD 2 2   3 NAD 2 NAD   3 NAD 2 1   3 NAD 2 0   3 NAD NAD 2   3 NAD NAD NAD   3 NAD NAD 1   3 NAD NAD 0   3 NAD 1 2   3 NAD 1 NAD   3 NAD 1 1   3 NAD 1 0   3 NAD 0 2   3 NAD 0 NAD   3 NAD 0 1   3 NAD 0 0   3 1 2 2   3 1 2 NAD   3 1 2 1   3 1 2 0   3 1 NAD 2   3 1 NAD NAD   3 1 NAD 1   3 1 NAD 0   3 1 1 2   3 1 1 NAD   3 1 1 1   3 1 1 0   3 1 0 2   3 1 0 NAD   3 1 0 1   3 1 0 0   3 0 2 2   3 0 2 NAD   3 0 2 1   3 0 2 0   3 0 NAD 2   3 0 NAD NAD   3 0 NAD 1   3 0 NAD 0   3 0 1 2   3 0 1 NAD   3 0 1 1   3 0 1 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data II 3 0 0 2   3 0 0 NAD   3 0 0 1   3 0 0 0 III NAD 3 3 3   2 3 3 3   1 3 3 3   0 3 3 3   NAD 3 3 2   NAD 3 3 NAD   NAD 3 3 1   NAD 3 3 0   NAD 3 2 3   NAD 3 NAD 3   NAD 3 1 3   NAD 3 0 3   2 3 3 2   2 3 3 NAD   2 3 3 1   2 3 3 0   2 3 2 3   2 3 NAD 3   2 3 1 3   2 3 0 3   1 3 3 2   1 3 3 NAD   1 3 3 1   1 3 3 0   1 3 2 3   1 3 NAD 3   1 3 1 3   1 3 0 3   0 3 3 2   0 3 3 NAD   0 3 3 1   0 3 3 0   0 3 2 3   0 3 NAD 3   0 3 1 3   0 3 0 3   NAD 3 2 2   NAD 3 2 NAD   NAD 3 2 1   NAD 3 2 0   NAD 3 NAD 2   NAD 3 NAD NAD   NAD 3 NAD 1   NAD 3 NAD 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data III NAD 3 1 2   NAD 3 1 NAD   NAD 3 1 1   NAD 3 1 0   NAD 3 0 2   NAD 3 0 NAD   NAD 3 0 1   NAD 3 0 0   2 3 2 2   2 3 2 NAD   2 3 2 1   2 3 2 0   2 3 NAD 2   2 3 NAD NAD   2 3 NAD 1   2 3 NAD 0   2 3 1 2   2 3 1 NAD   2 3 1 1   2 3 1 0   2 3 0 2   2 3 0 NAD   2 3 0 1   2 3 0 0   1 3 2 2   1 3 2 NAD   1 3 2 1   1 3 2 0   1 3 NAD 2   1 3 NAD NAD   1 3 NAD 1   1 3 NAD 0   1 3 1 2   1 3 1 NAD   1 3 1 1   1 3 1 0   1 3 0 2   1 3 0 NAD   1 3 0 1   1 3 0 0   0 3 2 2   0 3 2 NAD   0 3 2 1   0 3 2 0   0 3 NAD 2   0 3 NAD NAD   0 3 NAD 1   0 3 NAD 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data III 0 3 1 2   0 3 1 NAD   0 3 1 1   0 3 1 0   0 3 0 2   0 3 0 NAD   0 3 0 1   0 3 0 0 IV NAD 2 3 3   NAD NAD 3 3   NAD 1 3 3   NAD 0 3 3   2 2 3 3   2 NAD 3 3   2 1 3 3   2 0 3 3   1 2 3 3   1 NAD 3 3   1 1 3 3   1 0 3 3   0 2 3 3   0 NAD 3 3   0 1 3 3   0 0 3 3   NAD 2 3 2   NAD 2 3 NAD   NAD 2 3 1   NAD 2 3 0   NAD NAD 3 2   NAD NAD 3 NAD   NAD NAD 3 1   NAD NAD 3 0   NAD 1 3 2   NAD 1 3 NAD   NAD 1 3 1   NAD 1 3 0   NAD 0 3 2   NAD 0 3 NAD   NAD 0 3 1   NAD 0 3 0   2 2 3 2   2 2 3 NAD   2 2 3 1   2 2 3 0   2 2 2 3   2 2 NAD 3   2 2 1 3   2 2 0 3

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data IV 2 NAD 3 2   2 NAD 3 NAD   2 NAD 3 1   2 NAD 3 0   2 NAD 2 3   2 NAD NAD 3   2 NAD 1 3   2 NAD 0 3   2 1 3 2   2 1 3 NAD   2 1 3 1   2 1 3 0   2 1 2 3   2 1 NAD 3   2 1 1 3   2 1 0 3   2 0 3 2   2 0 3 NAD   2 0 3 1   2 0 3 0   2 0 2 3   2 0 NAD 3   2 0 1 3   2 0 0 3   NAD 2 2 3   NAD 2 NAD 3   NAD 2 1 3   NAD 2 0 3   NAD NAD 2 3   NAD NAD NAD 3   NAD NAD 1 3   NAD NAD 0 3   NAD 1 2 3   NAD 1 NAD 3   NAD 1 1 3   NAD 1 0 3   NAD 0 2 3   NAD 0 NAD 3   NAD 0 1 3   NAD 0 0 3   1 2 3 2   1 2 3 NAD   1 2 3 1   1 2 3 0   1 2 2 3   1 2 NAD 3   1 2 1 3   1 2 0 3

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data IV 1 NAD 3 2   1 NAD 3 NAD   1 NAD 3 1   1 NAD 3 0   1 NAD 2 3   1 NAD NAD 3   1 NAD 1 3   1 NAD 0 3   1 1 3 2   1 1 3 NAD   1 1 3 1   1 1 3 0   1 1 2 3   1 1 NAD 3   1 1 1 3   1 1 0 3   1 0 3 2   1 0 3 NAD   1 0 3 1   1 0 3 0   1 0 2 3   1 0 NAD 3   1 0 1 3   1 0 0 3   0 2 3 2   0 2 3 NAD   0 2 3 1   0 2 3 0   0 2 2 3   0 2 NAD 3   0 2 1 3   0 2 0 3   0 NAD 3 2   0 NAD 3 NAD   0 NAD 3 1   0 NAD 3 0   0 NAD 2 3   0 NAD NAD 3   0 NAD 1 3   0 NAD 0 3   0 1 3 2   0 1 3 NAD   0 1 3 1   0 1 3 0   0 1 2 3   0 1 NAD 3   0 1 1 3   0 1 0 3

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data IV 0 0 3 2   0 0 3 NAD   0 0 3 1   0 0 3 0   0 0 2 3   0 0 NAD 3   0 0 1 3   0 0 0 3 V 2 2 2 2   2 2 2 NAD   2 2 2 1   2 2 2 0   2 2 NAD 2   2 2 NAD NAD   2 2 NAD 1   2 2 NAD 0   2 2 1 2   2 2 1 NAD   2 2 1 1   2 2 1 0   2 2 0 2   2 2 0 NAD   2 2 0 1   2 2 0 0   2 NAD 2 2   2 NAD 2 NAD   2 NAD 2 1   2 NAD 2 0   2 NAD NAD 2   2 NAD NAD NAD   2 NAD NAD 1   2 NAD NAD 0   2 NAD 1 2   2 NAD 1 NAD   2 NAD 1 1   2 NAD 1 0   2 NAD 0 2   2 NAD 0 NAD   2 NAD 0 1   2 NAD 0 0   2 1 2 2   2 1 2 NAD   2 1 2 1   2 1 2 0   2 1 NAD 2   2 1 NAD NAD   2 1 NAD 1   2 1 NAD 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data V 2 1 1 2   2 1 1 NAD   2 1 1 1   2 1 1 0   2 1 0 2   2 1 0 NAD   2 1 0 1   2 1 0 0   2 0 2 2   2 0 2 NAD   2 0 2 1   2 0 2 0   2 0 NAD 2   2 0 NAD NAD   2 0 NAD 1   2 0 NAD 0   2 0 1 2   2 0 1 NAD   2 0 1 1   2 0 1 0   2 0 0 2   2 0 0 NAD   2 0 0 1   NAD 2 2 2   NAD 2 2 NAD   NAD 2 2 1   NAD 2 2 0   NAD 2 NAD 2   NAD 2 NAD NAD   NAD 2 NAD 1   NAD 2 NAD 0   NAD 2 1 2   NAD 2 1 NAD   NAD 2 1 1   NAD 2 1 0   NAD 2 0 2   NAD 2 0 NAD   NAD 2 0 1   NAD 2 0 0   NAD NAD 2 2   NAD NAD 2 NAD   NAD NAD 2 1   NAD NAD 2 0   NAD NAD NAD 2   NAD NAD NAD NAD   NAD NAD NAD 1   NAD NAD NAD 0   NAD NAD 1 2

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data V NAD NAD 1 NAD   NAD NAD 1 1   NAD NAD 1 0   NAD NAD 0 2   NAD NAD 0 NAD   NAD NAD 0 1   NAD NAD 0 0   NAD 1 2 2   NAD 1 2 NAD   NAD 1 2 1   NAD 1 2 0   NAD 1 NAD 2   NAD 1 NAD NAD   NAD 1 NAD 1   NAD 1 NAD 0   NAD 1 1 2   NAD 1 1 NAD   NAD 1 1 1   NAD 1 1 0   NAD 1 0 2   NAD 1 0 NAD   NAD 1 0 1   NAD 1 0 0   NAD 0 2 2   NAD 0 2 NAD   NAD 0 2 1   NAD 0 2 0   NAD 0 NAD 2   NAD 0 NAD NAD   NAD 0 NAD 1   NAD 0 NAD 0   NAD 0 1 2   NAD 0 1 NAD   NAD 0 1 1   NAD 0 1 0   NAD 0 0 2   NAD 0 0 NAD   NAD 0 0 1   NAD 0 0 0   1 2 2 2   1 2 2 NAD   1 2 2 1   1 2 2 0   1 2 NAD 2   1 2 NAD NAD   1 2 NAD 1   1 2 NAD 0   1 2 1 2

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data V 1 2 1 NAD   1 2 1 1   1 2 1 0   1 2 0 2   1 2 0 NAD   1 2 0 1   1 2 0 0   1 NAD 2 2   1 NAD 2 NAD   1 NAD 2 1   1 NAD 2 0   1 NAD NAD 2   1 NAD NAD NAD   1 NAD NAD 1   1 NAD NAD 0   1 NAD 1 2   1 NAD 1 NAD   1 NAD 1 1   1 NAD 1 0   1 NAD 0 2   1 NAD 0 NAD   1 NAD 0 1   1 NAD 0 0   1 1 2 2   1 1 2 NAD   1 1 2 1   1 1 2 0   1 1 NAD 2   1 1 NAD NAD   1 1 NAD 1   1 1 NAD 0   1 1 1 2   1 1 1 NAD   1 1 1 1   1 1 1 0   1 1 0 2   1 1 0 NAD   1 1 0 1   1 1 0 0   1 0 2 2   1 0 2 NAD   1 0 2 1   1 0 2 0   1 0 NAD 2   1 0 NAD NAD   1 0 NAD 1   1 0 NAD 0   1 0 1 2

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data V 1 0 1 NAD   1 0 1 1   1 0 1 0   1 0 0 2   1 0 0 NAD   1 0 0 1   1 0 0 0   1 0 0 0   0 2 2 2   0 2 2 NAD   0 2 2 1   0 2 2 0   0 2 NAD 2   0 2 NAD NAD   0 2 NAD 1   0 2 NAD 0   0 2 1 2   0 2 1 NAD   0 2 1 1   0 2 1 0   0 2 0 2   0 2 0 NAD   0 2 0 1   0 2 0 0   0 NAD 2 2   0 NAD 2 NAD   0 NAD 2 1   0 NAD 2 0   0 NAD NAD 2   0 NAD NAD NAD   0 NAD NAD 1   0 NAD NAD 0   0 NAD 1 2   0 NAD 1 NAD   0 NAD 1 1   0 NAD 1 0   0 NAD 0 2   0 NAD 0 NAD   0 NAD 0 1   0 NAD 0 0   0 1 2 2   0 1 2 NAD   0 1 2 1   0 1 2 0   0 1 NAD 2   0 1 NAD NAD   0 1 NAD 1   0 1 NAD 0

OCR for page 124
For Comment: Proposed Framework for Evaluating the Safety of Dietary Supplements Priority Group Human Data Animal Data Structure Data In Vitro Data V 0 1 1 2   0 1 1 NAD   0 1 1 1   0 1 1 0   0 1 0 2   0 1 0 NAD   0 1 0 1   0 1 0 0   0 0 2 2   0 0 2 NAD   0 0 2 1   0 0 2 0   0 0 NAD 2   0 0 NAD NAD   0 0 NAD 1   0 0 NAD 0   0 0 1 2   0 0 1 NAD   0 0 1 1   0 0 1 0   0 0 0 2   0 0 0 NAD   0 0 0 1   0 0 0 0